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DObjective: To assess the influence of gender on mortality after aortic valve replacement for aortic stenosis.
Methods: A retrospective analysis was performed on data prospectively collected from all patients undergoing
aortic valve replacement for aortic stenosis. Multivariate regression analysis was performed to evaluate the ef-
fect of 22 preoperative and operative variables on early, late, and overall mortality.
Results: Aortic valve replacement was performed in 3343 patients with aortic stenosis between 1982 and 2003.
The female patients were older, with a smaller body mass index. The women were less likely to have diabetes,
chronic obstructive pulmonary disease, previous myocardial infarction, or left ventricular ejection
fraction<35% but were more likely to have hypertension or a New York Heart Association III-IV classification.
The female patients received a smaller prosthetic valve, with a smaller effective orifice area index (EOAI). The
mean follow-up period was 6.18 4.96 years, with a total of 2066.142 years of follow-up. The independent pre-
dictors of early mortality for the male patients included age, concomitant surgical revascularization, congestive
heart failure, and valve size of 21 mm. The independent predictors of late mortality for the male patients in-
cluded age, concomitant surgical revascularization, diabetes, renal failure, chronic obstructive pulmonary dis-
ease, congestive heart failure, and a bioprosthetic valve. The independent predictors of overall mortality for
the male patients included age, concomitant surgical revascularization, diabetes, renal failure, heart failure,
and valve size of 21 mm. For the female patients, the risk factors for early mortality included body mass
index<25 kg/m2; for late mortality included age, concomitant surgical revascularization, New York Heart As-
sociation class III-IV, and diabetes; and for overall mortality included age, concomitant surgical revasculariza-
tion, New York Heart Association class III-IV, and renal failure. Furthermore, male gender was an independent
predictor of late (but not early or overall) mortality.
Conclusions: The independent predictors of mortality after aortic valve replacement for aortic stenosis differed
between the male and female patients. Male gender increased the risk of late mortality, and a valve size of21mm
increased the risk of early and overall mortality among the male patients only. These differences need to be taken
into consideration preoperatively and require consideration during operative management. (J Thorac Cardiovasc
Surg 2011;142:595-601)Supplemental material is available online.e Division of Cardiovascular Surgery, Department of Surgery, University of
h Columbia, Vancouver, British Columbia, Canada.
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The Journal of Thoracic and CaPatient characteristics often differ between males and fe-
males with aortic stenosis (AS) who present for aortic valve
replacement (AVR).1 However, the analysis of the influence
of gender on the outcomes in this population has been lim-
ited. The objective of the present study was to assess the dif-
ferences between genders in relation to mortality after AVR
for AS.METHODS
A retrospective analysis was performed on data prospectively collected
from all patients undergoing primary AVR for AS and mixed AS/insuffi-
ciency lesions between 1982 and 2003 at the University of British Colum-
bia–affiliated hospitals (Vancouver, British Columbia, Canada: St. Paul’s
Hospital, Vancouver General Hospital, and Royal Columbian Hospital).
The exclusion criteria included previous cardiac surgery. Patients undergo-
ing concomitant coronary artery bypass grafting (CABG) and aortic annulus
enlargement were included, as were patients with previous placement of
a permanent pacemaker. Only contemporary prosthetic aortic valves were
analyzed, including Carpentier-Edwards (SAV, Perimount, Edwards Life-
sciences, Irvine, Calif), St. Jude Medical (Standard, HP, Regent, St. Jude
Medical, St. Paul, Minn), Medtronic (Mosaic, Medtronic Inc, Minneapolis,rdiovascular Surgery c Volume 142, Number 3 595
Abbreviations and Acronyms
AS ¼ aortic stenosis
AVR ¼ aortic valve replacement
BMI ¼ body mass index
CABG ¼ coronary artery bypass grafting
CHF ¼ congestive heart failure
COPD ¼ chronic obstructive pulmonary disease
EOA ¼ effective orifice area
EOAI ¼ effective orifice area index
LVEF ¼ left ventricular ejection fraction
NYHA ¼ New York Heart Association
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DMinn), andCarboMedics (Standard,RSeries, TopHat, Sorin-CarboMedics,
Denver, Colo). All these valves are currentlymarketedworldwide, although
marketing of the Carpentier-Edwards SAVis limited toNorthAmerica. (We
have previously reported on the clinical performance of this prosthesis in an
institutional study and in a joint institutional study.2,3)
AVR was performed in 3343 patients with AS between 1982 and 2003
(2195 men and 1148 women). Both univariate and multivariate logistic re-
gression analyses were performed to evaluate the effect of 22 preoperative
and operative variables on early, late, and overall mortality. The univariate
variables with P  .25 were included in the multivariate analyses. The ef-
fective orifice area (EOA) index (EOAI) was forced into the multivariate
analyses (given the interest in this area among our group). The patients
were censored alive at reoperation.
The EOAs in our analyses were determined from the previously pub-
lished EOAs derived from in vivo echocardiography.2,4 The severity of
a prosthesis-patient mismatch has been related to the EOAI as follows: nor-
mal (EOAI  0.85 cm2/m2), mild to moderate (EOAI 0.65-0.85 cm2/m2),TABLE 1. Preoperative and operative characteristics of 3343 patients und
Characteristic Overall (n ¼ 3343) M
Age (y) 68.06  11.20 6
BMI (kg/m2) 27.09  5.13 2
Diabetes mellitus 10.0%
Hypertension 23.2%
Renal failure 9.2%
COPD 7.8%
Atrial fibrillation 7.8%
Previous myocardial infarction 9.2%
Carotid disease 0.4%
Previous stroke 6.3%
Congestive heart failure 33.8%
NYHA class III-IV 75.7%
Cardiogenic shock 0.1%
LVEF<35% 4.3%
Urgency of surgery (% urgent/emergency) 91.9%
Valve type (% bioprosthetic) 74.6%
Valve size (mm) 23.24  2.45 2
EOA (cm2/m2) 1.60  0.34
EOAI (cm2/m2) 0.86  0.17
Concomitant CABG 43.7%
Concomitant aortic annulus enlargement 1.0%
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; NYHA,New York H
EOAI, effective orifice area index; CABG, coronary artery bypass grafting.
596 The Journal of Thoracic and Cardiovascular Surgand severe (EOAI  0.65 cm2/m2). The standard definitions of mortality
outlined by the American Association for Thoracic Surgery were used.5,6
Early mortality was defined as all-cause mortality at 30 days after surgery,
and late mortality included all-cause mortality>30 days.RESULTS
The preoperative and operative characteristics of the
3343 patients undergoing AVR for AS are outlined in
Table 1. The female patients were older, with a smaller
body mass index (BMI). Additionally, the women were
less likely to have diabetes, chronic obstructive pulmonary
disease (COPD), previous myocardial infarction, or a left
ventricular ejection fraction (LVEF)<35%. However, the
women were more likely to have hypertension or a New
York Heart Association (NYHA) III-IV classification. The
female patients received a smaller prosthetic valve, with
a smaller EOA and a smaller EOAI. The women were
more likely to undergo aortic annulus enlargement but
were less likely to undergo concomitant CABG. The
mean follow-up of all patients was 6.18  4.96 years,
with a total of 2066.142 years of follow-up. The preopera-
tive and operative characteristics comparing the patients
by year of surgery and valve type are also listed in Tables
E1 and E2.Early Mortality
The crude early mortality rate for the overall study pop-
ulation was 3.4% (men 3.0%, and women 4.3%, P¼ .056).
From 1982 to 1992, the crude early mortality rate was 4.1%ergoing aortic valve replacement
ale (n ¼ 2195) Female (n ¼ 1148) P value (male vs female)
6.99  11.39 70.12  10.53 <.0001
7.22  4.79 26.83  5.73 .050
10.8% 8.5% .039
21.6% 26.4% .002
6.0% 5.1% .326
8.7% 6.0% .005
7.3% 8.7% .145
10.5% 6.5% .0001
0.5% 0.1% .043
6.7% 5.7% .264
32.8% 35.8% .077
74.0% 79.0% .001
0.046% 0.3% .087
5.2% 2.5% <.001
91.6% 92.5% .369
73.0% 77.6% .004
4.17  2.18 21.44  1.86 <.0001
1.71  0.33 1.39  0.24 <.0001
0.88  0.17 0.82  0.15 <.0001
48.2% 35.2% <.0001
0.5% 1.7% .001
eart Association; LVEF, left ventricular ejection fraction; EOA, effective orifice area;
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TABLE 2. Univariate analysis for predictors of mortality
Variable
Early
mortality
Late
mortality
Overall
mortality
Gender
Female Referent* Referent* Referent*
Male 0.049 0.250 0.635
Age <0.0001 <0.0001 <0.0001
60 Referent* Referent* Referent*
61-70 0.057 <0.0001 <0.0001
>70 <0.0001 <0.0001 <0.0001
BMI 0.001 0.196 0.025
<25 kg/m2 Referent* Referent* Referent*
25 kg/m2 0.001 0.431 0.073
LVEF
35% Referent* Referent* Referent*
<35% 0.33 0.00001 0.00001
NYHA class
I Referent* Referent* Referent*
II 0.972 0.578 0.636
III 0.459 0.409 0.295
IV 0.026 0.022 0.003
Dichotomized NYHA class
I-II Referent* Referent* Referent*
III-IV 0.011 0.00003 0.00002
Diabetes mellitus 0.652 <0.0001 <0.0001
Hypertension 0.431 0.0002 0.001
Preoperative atrial fibrillation 0.013 0.001 0.0001
Renal failure <0.001 <0.0001 <0.0001
COPD 0.501 <0.0001 <0.0001
Cardiogenic shock Not applicable 0.376 0.356
Carotid disease N/A 0.580 0.781
Myocardial infarction 0.134 <0.0001 <0.0001
Congestive heart failure 0.001 <0.0001 <0.0001
Year of surgery
1982-1992 Referent* Referent* Referent*
1993-2004 0.111 0.136 0.294
Status
Elective Referent* Referent* Referent*
Urgent 0.388 0.032 0.021
Emergent/salvage 0.001 0.007 <0.0001
Dichotomized status
Elective Referent* Referent* Referent*
Urgent/emergent/salvage 0.266 0.023 0.011
Valve type bioprosthetic 0.003 <0.0001 <0.0001
Mechanical Referent* Referent* Referent*
Valve size (mm)
21 Referent* Referent* Referent*
>21 <0.001 0.173 0.014
EOA (cm2/m2) <0.001 <0.0001 <0.0001
EOAI (cm2/m2) 0.549 <0.0001 <0.0001
EOAI (cm2/m2)
0.85 Referent* Referent* Referent*
0.65-0.85 0.790 0.242 0.217
0.65 0.685 0.033 0.061
Aortic annulus enlargement 0.929 0.433 0.489
Concomitant coronary artery
bypass grafting
<0.001 <0.001 <0.0001
*Reference category for categorical variables. Abbreviations as in Table 1.
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D(men 3.4%, and women 5.3%, P ¼ .126) for the overall
population and was 3.0% (men 2.7% and women 3.7%,
P ¼ .232) from 1993 to 2004.
Univariate logistic regression analysis (Table 2) revealed
increased early mortality for the patients with the following
risk factors: female gender, concomitant CABG, increasing
age, BMI <25 kg/m2, NYHA class III-IV, preoperative
atrial fibrillation, renal failure, congestive heart failure
(CHF), bioprosthetic valve, valve size of 21 mm, and
emergent status.
Multivariate logistic regression analysis demonstrated
that an earlier year of surgery, age >70 years,
BMI <25 kg/m2, CHF, concomitant CABG, valve size
of 21 mm, and urgent/emergent status were independent
predictors of early mortality (Table 3). Among the men,
age>70 years, concomitant CABG, CHF, and valve size
of 21 mm all remained independent predictors of early
mortality. However, a BMI <25 kg/m2 was the only
independent predictor of early mortality among the female
patients.
Late Mortality
Univariate logistic regression analysis showed increased
late mortality in patients with the following risk factors
(Table 2): concomitant CABG, increasing age, EOAI
of0.65 cm2/m2, LVEF<35%, NYHA class III-IV, diabe-
tes, hypertension, preoperative atrial fibrillation, renal fail-
ure, COPD, myocardial infarction, CHF, bioprosthetic
valve, and urgent or emergent status.
The multivariate hazard regression analysis demon-
strated the following independent predictors of late mortal-
ity: increased age, concomitant CABG, LVEF <35%,
NYHA class III-IV, diabetes, renal failure, COPD, CHF, bi-
oprosthetic valve, and male gender (Table 4). Most of these
factors remained predictive of late mortality for the male
patients, specifically increased age, concomitant CABG, di-
abetes, renal failure, COPD, CHF, and bioprosthetic valve.
Among the female patients, the only independent predictors
of late mortality were increased age, concomitant CABG,
NYHA class III-IV, and diabetes.
Overall Mortality
Compared with late mortality, a valve size of 21 mm
was the only additional univariate predictor of overall mor-
tality (Table 2). Figure 1 displays the survival for the male
and female patients by prosthetic valve size. Among those
receiving a prosthetic valve of21 mm, the overall mortal-
ity was significantly decreased for the male patients
(P ¼ .007), with 23.4% survival at 15 years compared
with a rate of 38.3% for the female patients. No significant
difference was seen in overall survival between the men and
women receiving a prosthetic valve>21 mm (P ¼ .67)
(Figure 1). Among the men, survival was significantly de-
creased with the use of a prosthetic valve of 21 mmrdiovascular Surgery c Volume 142, Number 3 597
TABLE 3. Multivariate predictors of early mortality
Early (overall) Male Female
OR (95% CI) P value OR (95% CI) P value OR (95% CI) P value
Age>70 y 4.26 (1.81-10.02) .001 4.11 (1.46-11.58) .007 — —
BMI>25 kg/m2 0.62 (0.42-0.92) .018 — — 0.44 (0.24 - 0.82) .009
Congestive heart failure 1.62 (1.06-2.48) .026 1.90 (1.08-3.36) .026 — —
Surgical period (1993-2004) 0.62 (0.40-0.95) .030 — — — —
Urgent/emergent status 3.01 (1.10-8.24) .032 — — — —
Valve size>21 mm 0.53 (0.33-0.84) .007 0.50 (0.28-0.92) .025 — —
Concomitant coronary artery
bypass grafting
1.91 (1.26-2.91) .002 2.20 (1.22-3.97) .009 — —
OR, Odds ratio; CI, confidence interval; BMI, body mass index.
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Dcompared with a valve size>21 mm (P¼ .0002). This phe-
nomenon was not observed among the women (P ¼ .392).
Figures E1-E4 graphically display the overall survival by
gender, age, and LVEF. No significant difference was
found in overall survival between the male and female
patients (P ¼ .64). Overall survival decreased with
increasing age (P < .0001). Overall survival was also
significantly decreased for both men (P<.001) and women
(P<.005) with a LVEF<35%.
Multivariate hazard regression analysis revealed that in-
creased age, concomitant CABG, LVEF<35%, NYHAclass
III-IV, diabetes, renal failure, CHF, and the use of a biopros-
thetic valvewere predictive of overallmortality (Table 5). For
the men, the independent risk factors for overall mortality
were increased age, concomitant CABG, diabetes, renal fail-
ure, CHF, and valve size of21mm(Table 5). In contrast, for
the women, the independent risk factors for overall mortality
included only increased age, concomitant CABG, NYHA
class III-IV, and renal failure (Table 5).
DISCUSSION
Although AVR for AS is performed frequently in cardiac
surgery, very few studies have evaluated the predictors of
mortality in this population. Furthermore, to the best of
our knowledge, no previously published studies have inves-TABLE 4. Multivariate predictors of late mortality
Late (overall)
HR (95% CI) P value HR
Male gender 1.25 (1.07-1.45) 0.006
Age 61-70 y 2.15 (1.75-2.65) <0.0001 2.11
Age>70 y 3.87 (3.13-4.79) <0.0001 3.55
LVEF<35% 1.41 (1.05-1.89) 0.022
NYHA III/IV 1.23 (1.04-1.46) 0.014
Diabetes mellitus 1.51 (1.18-1.93) 0.001 1.43
Renal failure 1.47 (1.17-1.85) 0.001 1.49
COPD 1.35 (1.06-1.72) 0.015 1.39
CHF 1.37 (1.18-1.60) <0.0001 1.48
Bioprosthetic valve 1.26 (1.06-1.49) 0.009 1.29
Concomitant CABG 1.24 (1.09-1.41) 0.001 1.20
HR, Hazard ratio; CI, confidence interval; CHF, congestive heart failure; other abbreviatio
598 The Journal of Thoracic and Cardiovascular Surgtigated the differences between male and female patients
with AS presenting for AVR or their risk factors for mortal-
ity after surgery.
At least 5 groups have previously studied the risk factors
for early mortality after AVR.7-11 However, these
populations all included those with pure aortic
insufficiency; thus, the relevance to the AS population is
somewhat limited. A systematic review that included 28
studies, 16 of which were considered high quality,
determined that the only strong predictor for early mortality
after AVR was emergent status.7 Other moderate predictors
of earlymortality included increased age, aortic insufficiency,
coronary artery disease, increased cardiopulmonary bypass
time, decreased LVEF, endocarditis, hypertension, mechani-
cal valves, preoperative pacing, dialysis-dependent renal
failure, and an increased valve size.7 Our study also demon-
strated that age>70 years, emergent surgery, renal failure,
and concomitant CABG (as a marker of the presence of cor-
onary artery disease) were all predictive of early mortality.
However, a BMI< 25 kg/m2 and a prosthetic valve size
of 21mmwere also independent predictors of earlymortal-
ity. Decreased LVEF, hypertension, and valve type were not
predictive of early mortality in our population. Other previ-
ously demonstrated risk factors for early mortality, such as
advanced NYHA class,8 preoperative atrial fibrillation,8Male Female
(95% CI) P value HR (95% CI) P value
— — — —
(1.67-2.67) <0.0001 2.35 (1.51–3.67) <0.001
(2.77-4.54) <0.0001 4.78 (3.06–7.46) <0.0001
— — — —
— — 1.48 (1.04–2.10) 0.028
(1.06-1.93) 0.018 1.79 (1.16–2.75) 0.008
(1.13-1.96) 0.005 — —
(1.04-1.84) 0.024 — —
(1.22-1.78) 0.000 — —
(1.05-1.58) 0.017 — —
(1.02-1.41) 0.024 1.30 (1.03-1.65) 0.029
ns as in Table 1.
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FIGURE 1. Overall survival for men and women stratified by prosthetic
valve size. Survival for women was superior to that of men for 15 years
for valve size 21 mm (P ¼ .007). Survival for women and men was not
different for 15 years for valve size>21 mm (P ¼ .669). Among men, sur-
vival was significantly decreased with a prosthetic valve of 21 mm com-
pared with>21 mm (P¼ .0002). Among women, no difference was seen in
survival by valve size (P ¼ .392).
TABLE 5. Multivariate predictors of overall mortality
Overall
HR (95% CI) P value HR
Age 61-70 y 2.08 (1.70-2.55) <.0001 2.08
Age>70 y 3.80 (3.10-4.67) <.0001 3.63
LVEF<35% 1.36 (1.03-1.79) .030
NYHA class III-IV 1.24 (1.06-1.46) .007
Diabetes mellitus 1.41 (1.12-1.77) .003 1.38
Renal failure 1.55 (1.26-1.91) .000 1.26
CHF 1.40 (1.22-1.61) <.0001 1.55
Bioprosthetic valve 1.22 (1.31-1.43) .016
Valve size>21 mm — — 0.77
Concomitant CABG 1.33 (1.18-1.51) <.0001 1.25
Abbreviations as in Tables 1 and 4.
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DCHF,9 and diabetes,9 were not statistically significant in our
multivariate analysis of 3343 patients.
That systematic review also determined that increased
age, emergent surgery, and preoperative atrial fibrillation
were predictive of late mortality.7 Although our analysis
revealed increased age as a risk factor for late mortality,
neither emergent surgery nor preoperative atrial fibrillation
were predictive of late mortality. Furthermore, our study
also substantiated that NYHA class III-IV and concomitant
CABGwere predictive of late mortality. In contrast, the sys-
temic review revealed inconclusive evidence for this claim.7
Two other studies investigating latemortality after AVR also
demonstrated that coronary artery disease12 or concomitant
CABG8 and NYHA class IIIB-IV8 or CHF10 were risk fac-
tors for late mortality. However, these 2 studies also reported
atrial fibrillation as predictive of late mortality.8,12 Both of
these studies were smaller than ours, however, and
included patients with pure aortic insufficiency. A recently
published study that excluded patients with aortic
insufficiency concluded that mortality within this first year
was increased for those patients who were older, had had
left ventricular dilatation, had received a smaller
prosthetic valve, had a calcified ascending aorta, or had
had an earlier date of operation. In contrast, increased age,
an increased degree of AS, an increased left ventricular
mass, a smaller EOAI, left ventricular dysfunction, and
moderate to severe symptoms were all predictive of late
mortally> 1 year after AVR.13 Most of these variables
were not included in our analysis because these data were
not available for the earliest group of patients.
Our findings have clearly demonstrated the differences
between male and female patients with AS presenting for
AVR. The female patients were older, with a smaller
BMI, and had a greater incidence of hypertension or
NYHA class III-IV, although the male patients were more
likely to have diabetes, COPD, previous myocardial infarc-
tion, or LVEF < 35%. This increased incidence ofMale Female
(95% CI) P value HR (95% CI) P value
(1.66-2.63) <.0001 2.29 (1.49-3.51) .000
(2.86-4.60) <.0001 4.64 (3.04-7.10) <.0001
— — — —
— — 1.56 (1.13-2.15) .007
(1.04-1.82) .025 — —
(1.14-1.92) .003 1.66 (1.15-2.39) .007
(1.31-1.84) <.0001 — —
— — — —
(0.64-0.93) .006 — —
(1.07-1.46) .004 1.36 (1.10-1.69) .006
rdiovascular Surgery c Volume 142, Number 3 599
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Dpreoperative co-morbidities in the female patients has been
previously demonstrated.1 Although female patients would
be expected to receive a smaller prosthetic valve, the result-
ing smaller EOAI and an increased incidence of aortic an-
nulus enlargement were mildly surprising. Female gender
was a univariate predictor of early mortality, and male
gender was a multivariate predictor of late mortality. Dun-
can et al1 have also reported female gender as a univariate
risk factor for early mortality. However, after propensity
matching, they concluded that patient gender was not an in-
dependent predictor of in-hospital mortality.1 Similarly,
Florath and colleagues11 demonstrated increased operative
mortality in a very select subset of female patients, specif-
ically those receiving AVR and concomitant CABG with
a BMI>29 kg/m.7 At least one study reported male gender
as an independent predictor of late mortality in all patients
presenting for AVR.14 However, a systematic review of the
available data claimed the data were insufficient to substan-
tiate gender as an independent predictor of early or late mor-
tality after AVR.7
Although many of the previously cited risk factors for
mortality were statistically significant for the male patients
in our population, the predictors of mortality for the female
patients were limited in our study. For the women,
a BMI< 25 kg/m2 was the only independent predictor of
early mortality, and increased age, concomitant CABG,
NYHA class III-IV, and diabetes were the only predictors
of late mortality. Finally, the independent predictors of
overall mortality for the women were limited to increased
age, concomitant CABG, NYHA class III-IV, and renal fail-
ure. Thus, patient gender should be considered when esti-
mating an individual patient’s risk of mortality after AVR.
These differences in predictors of mortality between men
and women were likely due to the innate differences be-
tween these 2 genders, as evidenced, in part, by the differ-
ences in preoperative characteristics.
Receiving a bioprosthetic valve, instead of a mechanical
valve, was a risk factor for both late and overall mortality.
Because the patients were censored alive at reoperation,
the increased mortality was not related to a second surgery.
As expected, the preoperative characteristics differed be-
tween the patients receiving bioprosthethic valves com-
pared with those receiving mechanical valves in our study
(online Table). However, we have postulated that the
increased mortality seen with bioprosthetic valves in the
aortic position might have been related to the degenerative
changes in the valves, leading to either significant stenosis
or regurgitation that might have been missed during late
routine patient follow-up. This is an important issue that
requires additional investigation and evaluation and was
beyond the scope of the present study.
The finding of a valve size of 21 mm as a predictor
of early and overall mortality in the male patients is an im-
portant finding. Thus, the operative management of small600 The Journal of Thoracic and Cardiovascular Surgannular sizes in male patients needs serious consideration
with regard to annular enlargement, the optimal stented
or stentless prosthesis, and stentless bioprosthesis root
replacement.
The major limitations of the present study were those in-
herent to a retrospective cohort study. However, every effort
was made to ensure complete and accurate information in
the database. A second limitation of our study was related
to aortic annular enlargement. The decision to perform an-
nular enlargement varies among surgeons; thus, the indica-
tions have been inconsistent. However, the number of
annular enlargements performed in this patient population
was extremely small, making it unlikely to have resulted
in a statistically significant effect on mortality. A third lim-
itation was the inter-relationship between BMI, EOA, and
prosthesis–patient mismatch. However, despite their inter-
dependency, we believe these remain separate, independent
variables. Although an increased BMI increased the risk of
severe prosthesis–patient mismatch, a low BMI might be
a marker of other risk factors, such as frailty and poor
nutrition, which increase the mortality. This could explain
how an increased valve size and increased BMI were both
protective, but EOAI remained statistically nonsignificant.
CONCLUSIONS
Men and women with AS presenting for AVR differed
with respect to preoperative characteristics, as well as the
size of the prosthetic valve and types of concomitant proce-
dures they received. Furthermore, the independent predic-
tors of mortality differed between the male and female
patients in this population. Male gender was a risk factor
for late, but not early or overall, mortality. These differences
between the male and female patients, specifically with re-
gard to valve size, need to be considered preoperatively
when attempting to determine the individual patient risks
and operative management.
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TABLE E1. Baseline patient characteristics by surgical period
Variable 1982–1992 (n ¼ 1201) 1993–2004 (n ¼ 2142) P value
Follow-up 9.80 (5.18) 4.15 (3.44) <.0001
Female 34.5% 34.3% .905
Age (years) 66.38 (10.89) 69.01 (11.26) <.0001
Body mass index (kg/m2) 26.30 (5.11) 27.53 (5.10) <.0001
Diabetes mellitus 3.0% 14.0% <.0001
Hypertension 11.8% 29.6% <.0001
Renal failure 7.5% 4.7% .001
Chronic obstructive pulmonary disease 4.3% 9.8% <.0001
Atrial fibrillation 9.7% 6.7% .001
Previous myocardial infarction 5.6% 11.2% <.0001
Carotid disease 0.2% 0.5% .154
Previous stroke 3.2% 8.1% <.0001
Congestive heart failure 17.5% 43.0% <.0001
New York Heart Association class III-IV 84.6% 70.7% <.0001
Cardiogenic shock 0.2% 0.1% .622
Left ventricular ejection fraction<35% 2.9% 5.1% .003
Urgency of surgery (% urgent/emergency) 88.1% 94.1% <.0001
Valve type (% bioprosthetic) 76.7% 73.4% .036
Valve size (mm) 23.58 (2.52) 23.04 (2.39) <.0001
Effective orifice area (cm2/m2) 1.61 (0.30) 1.60 (0.36) .117
Effective orifice area index (cm2/m2) 0.88 (0.16) 0.85 (0.17) <.0001
Concomitant coronary artery bypass grafting 37.3% 47.3% <.0001
Concomitant aortic annulus enlargement 0.1% 1.4% .0001
TABLE E2. Baseline patient characteristics stratified by valve type
Variable Bioprosthetic (n ¼ 2493) Mechanical (n ¼ 2142) P value
Follow-up 5.49 (4.91) 8.20 (4.52) <.0001
Female 64.3% 69.8% .004
Age (y) 71.16 (9.45) 58.97 (10.98) <.0001
Body mass index (kg/m2) 26.78 (4.97) 28.00 (5.49) <.0001
Diabetes mellitus 10.8% 7.9% .016
Hypertension 26.3% 14.4% <.0001
Renal failure 6.5% 3.3% .0005
Chronic obstructive pulmonary disease 9.0% 4.2% <.0001
Atrial fibrillation 6.9% 10.5% .001
Previous myocardial infarction 10.6% 4.9% <.0001
Carotid disease 0.4% 0.4% 1
Previous stroke 7.4% 3.2% <.0001
Congestive heart failure 36.3% 26.5% <.0001
New York Heart Association class III-IV 78.2% 68.5% <.0001
Cardiogenic shock 0.1% 0.2% .269
Left ventricular ejection fraction<35% 4.5% 3.9% .48
Urgency of surgery (% urgent/emergency) 93.0% 88.7% .0001
Valve type (% bioprosthetic) 63.1% 67.1% .036
Valve size (mm) 23.18 (2.44) 23.39 (2.47) .035
Effective orifice area (cm2/m2) 1.54 (0.25) 1.79 (0.47) <.0001
Effective orifice area index (cm2/m2) 0.84 (0.13) 0.93 (0.23) <.0001
Concomitant coronary artery bypass grafting 48.5% 29.6% .504
Concomitant aortic annulus enlargement 1.0% 0.7% <.0001
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